Characterization of the neutralizing activity of digoxin-specific fab toward ouabain-like steroids

Journal of Pharmacology and Experimental Therapeutics

Volumn 310, Issue 1, 2004, Pages 319-325

  Pullen, Mark A ^a,b   Brooks, David P ^a   Edwards, Richard M ^a  

^a GLAXOSMITHKLINE   (United States)

^b Mail Code UW2521 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSTROPHANTHIDIN; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); BUFALIN; BUFODIENOLIDE; CARDENOLIDE; CINOBUFAGEN; CINOBUFATOLIN; CONVALLATOXIN; DIGITALIS LIKE FACTOR; DIGITOXIGENIN; DIGITOXIN; DIGOXIGENIN; DIGOXIN; DIGOXIN ANTIBODY F(AB) FRAGMENT; MARINOBUFAGENIN; NERIIFOLIN; OUABAGENIN; OUABAIN; OUABAIN LIKE STEROID; PROSCILLARDIN; SODIUM POTASSIUM ATPASE REGULATORY FACTOR; STROPHANTHIDIN; UNCLASSIFIED DRUG;

ANTIGEN BINDING; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CONTROLLED STUDY; DIGITALIS INTOXICATION; DRUG POTENCY; DRUG STRUCTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTENSION; PREECLAMPSIA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN INTERACTION; SHEEP; STRUCTURE ANALYSIS;

ANIMALS; DIGOXIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; HYPERTENSION; IMMUNOGLOBULIN FAB FRAGMENTS; NA(+)-K(+)-EXCHANGING ATPASE; OUABAIN; RATS; STEROIDS; TRITIUM;

EID: 3042552731     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.104.065250     Document Type: Article

References (40)

1. Adair CD, Buckalew V, Taylor K, Ernest JM, Frye AH, Evans C, and Veille JC (1996) Elevated endoxin-like factor complicating a multifetal second trimester pregnancy: treatment with digoxin-binding immunoglobulin. Am J Nephrol 16:529-531.
2. Bagrov AY and Fedorova OV (1998) Effects of two putative endogenous digitalis-like factors, marinobufagenin and ouabain, on the Na+, K+-pump in human mesenteric arteries. J Hypertens 16:1953-1958.
3. Bagrov AY, Fedorova OV, Dmitrieva RI, French AW, and Anderson DE (1996) Plasma marinobufagenin-like and ouabain-like immunoreactivity during saline volume expansion in anesthetized dogs. Cardiovasc Res 31:296-305.
4. Bagrov AY, Fedorova OV, Dmitrieva RI, Howald WN, Hunter AP, Kuznetsova EA, and Shpen VM (1998) Characterization of a urinary bufodienolide Na+,K+-ATPase inhibitor in patients after acute myocardial infarction. Hypertension 31:1097-1103.
5. Balzan S, D'Urso G, Ghione S, Martinelli A, and Montali U (2000) Selective inhibition of human erythrocyte Na+/K+ ATPase by cardiac glycosides and by a mammalian digitalis like factor. Life Sci 67:1921-1928.
6. Balzan S, Montali U, Biver P, and Ghione S (1991) Digoxin-binding antibodies reverse the effect of endogenous digitalis-like compounds on Na,K-ATPase in erythrocytes. J Hypertens 9:S304-S305.
7. Brubacher JR, Lachmanen D, Ravikumar PR, and Hoffman RS (1999) Efficacy of digoxin specific Fab fragments (Digibind) in the treatment of toad venom poisoning. Toxicon 37:931-942.
8. Brubacher JR, Ravikumar PR, Bania T, Heller MB, and Hoffman RS (1996) Treatment of toad venom poisoning with digoxin-specific Fab fragments. Chest 110:1282-1288.
9. Curd J, Smith TW, Jaton JC, and Haber E (1971) The isolation of digoxin-specific antibody and its use in reversing the effects of digoxin. Proc Natl Acad Sci USA 68:2401-2406.
10. Dasgupta A and Emerson L (1998) Neutralization of cardiac toxins oleandrin, oleandrigenin, bufalin and cinobufotalin by Digibind: monitoring the effect by measuring free digitoxin concentrations. Life Sci 63:781-788.
11. Di Bartolo V, Balzan S, Pieraccini L, Ghione S, Pegoraro S, Biver P, Revoltella R, and Montali U (1995) Evidence for an endogenous ouabain-like immunoreactive factor in human newborn plasma coeluted with ouabain on HPLC. Life Sci 57:1417-1425.
12. El-Masri MA, Clark BJ, Qazzaz HM, and Valdes R Jr (2002) Human adrenal cells in culture produce both ouabain-like and dihydroouabain-like factors. Clin Chem 48:1720-1730.
13. Farr CD, Burd C, Tabet MR, Ball WJ Jr, Fishwild DM, Wang X, Nair AC, and Welsh WJ (2002a) Three-dimensional quantitative structure-activity relationship analysis of ligand binding to human sequence antidigoxin monoclonal antibodies using comparative molecular field analysis. J Med Chem 45:3257-3270.
14. Farr CD, Burd C, Tabet MR, Wang X, Welsh WJ, and Ball WJ Jr (2002b) Three-dimensional quantitative structure-activity relationship study of the inhibition of Na(+),K(+)-ATPase by cardiotonic steroids using comparative molecular field analysis. Biochemistry 41:1137-1148.
15. Fedorova OV and Bagrov AY (1997) Inhibition of Na/K ATPase from rat aorta by two Na/K pump inhibitors, ouabain and marinobufagenin: evidence of interaction with different alpha-subunit isoforms. Am J Hypertens 10:929-935.
16. Fedorova OV, Kolodkin NI, Agalakova NI, Lakatta EG, and Bagrov AY (2001) Marinobufagenin, an endogenous alpha-1 sodium pump ligand, in hypertensive Dahl salt-sensitive rats. Hypertension 37:462-466.
17. Forbush B 3rd (1983) Assay of Na,K-ATPase in plasma membrane preparations: increasing the permeability of membrane vesicles using sodium dodecyl sulfate buffered with bovine serum albumin. Anal Biochem 128:159-163.
18. Fridman AI, Matveev SA, Agalakova NI, Fedorova OV, Lakatta EG, and Bagrov AY (2002) Marinobufagenin, an endogenous ligand of alpha-1 sodium pump, is a marker of congestive heart failure severity. J Hypertens 20:1189-1194.
19. Goodlin RC (1988) Antidigoxin antibodies in eclampsia. N Engl J Med 318:518-519.
20. Graves SW, Lincoln K, Cook SL, and Seely EW (1995) Digitalis-like factor and digoxin-like immunoreactive factor in diabetic women with preeclampsia, transient hypertension of pregnancy and normotensive pregnancy. Am J Hypertens 8:5-11.
21. Hamlyn JM, Blaustein MP, Bova S, DuCharme DW, Harris DW, Mandel F, Mathews WR, and Ludens JH (1991) Identification and characterization of a ouabain-like compound from human plasma. Proc Natl Acad Sci USA 88:6259-6263.
22. Hilton PJ, White RW, Lord GA, Garner GV, Gordon DB, Hilton MJ, Forni LG, McKinnon W, Ismail FM, Keenan M, et al. (1996) An inhibitor of the sodium pump obtained from human placenta. Lancet 348:303-305.
23. Huang BS and Leenen FH (1996) Brain "ouabain" and angiotensin II in salt-sensitive hypertension in spontaneously hypertensive rats. Hypertension 28:1005-1012.
24. Kaide J, Ura N, Torii T, Nakagawa M, Takada T, and Shimamoto K (1999) Effects of digoxin-specific antibody Fab fragment (Digibind) on blood pressure and renal water-sodium metabolism in 5/6 reduced renal mass hypertensive rats. Am J Hypertens 12:611-619.
25. Kaminski K and Rechberger T (1991) Concentration of digoxin-like immunoreactive substance in patients with preeclampsia and its relation to severity of pregnancy-induced hypertension. Am J Obstet Gynecol 165:733-736.
26. Ke YS (2001) Endoxin: a major factor regulating cardiovascular system. Acta Pharmacol Sin 22:201-209.
27. Krep HH, Graves SW, Price DA, Lazarus M, Ensign A, Soszynski PA, and Hollenberg NK (1996) Reversal of sodium pump inhibitor induced vascular smooth muscle contraction with Digibind. Stoichiometry and its implications. Am J Hypertens 9:39-46.
28. Levi AJ, Boyett MR, and Lee CO (1995) The cellular actions of digitalis glycosides in the heart. Prog Biophys Mol Biol 62:1-54.
29. Li M, Wen C, and Whitworth JA (1997) Hemodynamic effects of the Fab fragment of digoxin antibody (Digibind) in corticotropin (ACTH)-induced hypertension. Am J Hypertens 10:332-336.
30. Lingrel JB and Kuntzweiler T (1994) Na+,K(+)-ATPase. J Biol Chem 269:19659-19662.
31. Lopatin DA, Ailamazian EK, Dmitrieva RI, Shpen VM, Fedorova OV, Doris PA, and Bagrov AY (1999) Circulating bufodienolide and cardenolide sodium pump inhibitors in preeclampsia. J Hypertens 17:1179-1187.
32. Melero CP, Medarde M, and San Fliciano A (2000) A short review on cardiotonic steroids and their aminoguanadine analogues. Molecules 5:51-81.
33. Morris RG, Frewin DB, Saccoia NC, Goldsworthy WL, Jeffries WS, and McPhee AJ (1990) Interference from digoxin-like immunoreactive substance(s) in commercial digoxin kit assay methods. Eur J Clin Pharmacol 39:359-363.
34. Naomi S, Graves S, Lazarus M, Williams GH, and Hollenberg NK (1991) Variation in apparent serum digitalis-like factor levels with different digoxin antibodies. The "immunochemical fingerprint". Am J Hypertens 4:795-801.
35. Oda M, Kurosawa M, Numazawa S, Tanaka S, Akizawa T, Ito K, Maeda M, and Yoshida T (2001) Determination of bufalin-like immunoreactivity in serum of humans and rats by time-resolved fluoroimmunoassay for using a monoclonal antibody. Life Sci 68:1107-1117.
36. Sich B, Kirch U, Tepel M, Ziedek W, and Schoner W (1996) Pulse pressure correlates with a proscillardin A immunoreactive compound. Hypertension 27:1073-1078.
37. Schoner W (2002) Endogenous cardiac glycosides, a new class of steroid hormones. Eur J Biochem 269:2440-2448.
38. Tao QF, Soszynski PA, Hollenberg NK, and Graves SW (1996) Specificity of the volume-sensitive sodium pump inhibitor isolated from human peritoneal dialysate in chronic renal failure. Kidney Int 49:420-429.
39. Teruya H, Yamazato M, Muratani H, Sakima A, Takishita S, Terano Y, and Fukiyama K (1997) Role of ouabain-like compound in the rostral ventrolateral medulla in rats. J Clin Investig 99:2791-2798.
40. Yingst DR, Yang SY, and Schiebinger R (1998) Purification of active Na+-K+-ATPase using a new ouabain-affinity column. Am J Physiol 275:C1167-C1177.